Trial reportHaematologica2009
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Trial report in Haematologica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 69 citations in OpenAlex.
- Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis.American journal of hematology · 2025Article
- A novel prognostic model to predict prognosis of patients with osteosarcoma based on clinical characteristics and blood biomarkers.Journal of Cancer · 2025Article
- Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis.Kidney international reports · 2024Review
- Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment.Oncology letters · 2024Article
- Associations of serum cystatin C concentrations with total mortality and mortality of 12 site-specific cancers.Frontiers in molecular biosciences · 2024Article
- Association between preoperative serum Cystatin-C levels and postsurgical oncological prognosis in patients with PRCC: A retrospective cohort study.Cancer medicine · 2022Article
- Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.Advances in hematology · 2022Article
- Prognostic Value of Pretreatment Serum Cystatin C Level in Nasopharyngeal Carcinoma Patients in the Intensity-modulated Radiotherapy Era.OncoTargets and therapy · 2021Article
- Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction.Journal of clinical medicine · 2020Article
- New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies.Journal of clinical medicine · 2020Review
- Cystatin C: A Primer for Pharmacists.Pharmacy (Basel, Switzerland) · 2020Review
- Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma.Mediators of inflammation · 2020Article
- Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma.International journal of nephrology · 2018Article
- Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.BBA clinical · 2017Article
- Prognostic value of cystatin C in patients with nasopharyngeal carcinoma: a retrospective study of 1063 patients.Clinics (Sao Paulo, Brazil) · 2016Article
- Current Trends of Renal Impairment in Multiple Myeloma.Kidney diseases (Basel, Switzerland) · 2016Review
- Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Case reports in nephrology · 2014Article
- Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer.International journal of circumpolar health · 2013Article
- Cystatin C and lactoferrin concentrations in biological fluids as possible prognostic factors in eye tumor development.International journal of circumpolar health · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal impairment is a common complication of multiple myeloma. Cystatin-C is considered an accurate marker of glomerular filtration rate in several renal disorders. Microarray analysis has revealed that cystatin-C is one of the most highly up-regulated genes in multiple myeloma. The aim of this study was to evaluate the serum levels of cystatin-C in myeloma patients, explore possible correlations with clinical data, including survival, and assess the effect of bortezomib on cystatin-C in relapsed multiple myeloma. DESIGN AND
methodsWe measured serum cystatin-C in 157 newly diagnosed, previously untreated myeloma patients, in 28 patients with relapsed disease pre- and post-bortezomib therapy and in 52 healthy controls, using a latex particle-enhanced nephelometric immunoassay.
resultsIn newly diagnosed patients, cystatin-C was elevated and showed strong correlations with advanced ISS stage, extensive bone disease, high beta(2)-microglobulin, high serum creatinine, and low creatinine clearance. Multivariate analysis revealed that only cystatin-C and lactate dehydrogenase had an independent prognostic impact on patients' survival. The combination of cystatin-C and lactate dehydrogenase revealed three prognostic groups of patients: a high-risk group (both elevated cystatin-C and lactate dehydrogenase) with a median survival of 24 months, an intermediate-risk group (elevated cystatin-C or elevated lactate dehydrogenase) with a median survival of 48 months and a low-risk group (both low cystatin-C and lactate dehydrogenase) in which median survival has not yet been reached (p<0.001). Cystatin-C could also identify a subset of ISS-II patients with worse outcome. Relapsed patients had higher cystatin-C levels even compared to newly diagnosed patients. Treatment with bortezomib produced a significant reduction of cystatin-C, mainly in responders.
conclusionsSerum cystatin-C is not only a sensitive marker of renal impairment but also reflects tumor burden and is of prognostic value in myeloma. Its reduction after treatment with bortezomib reflects bortezomib's anti-myeloma activity and possibly bortezomib's direct effect on renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.